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Abstract (300 word limit) 
The Cl--extruding transporter KCC2 (SLC12A5) critically modulates 
GABAA receptor signaling via its effect on neuronal Cl- homeostasis. 
Previous studies have shown that KCC2 was downregulated in both 
epileptic patients and various epileptic animal models. We discovered 
that the in vitro dual phosphorylation of Thr906 and Thr1007 in the 
intracellular carboxyl (C)-terminal domain of KCC2, mediated by the 
Cl--sensitive WNK-SPAK serine-threonine protein kinase complex, 
maintains the depolarizing action of GABA in immature neurons by 
antagonizing KCC2 Cl- extrusion capacity. GABAAR-mediated inhibition 
confines KCC2 to the plasma membrane, while antagonizing inhibition 
reduces KCC2 surface expression by increasing the lateral diffusion 
and endocytosis of the transporter. This mechanism utilizes Cl-  as an 
intracellular secondary messenger and is dependent on 
phosphorylation of KCC2 at threonines 906 and 1007 by the Cl- -
sensing kinase WNK1. We propose this mechanism contributes to the 
homeostasis of synaptic inhibition by rapidly adjusting neuronal [Cl-]i to 
GABAAR activity. We further demonstrate here that this signaling 
pathway is rapidly and massively activated in an acute epilepsy 
model. This indicates that dephosphorylation of KCC2 at Thr906 and 
Thr1007 is a potent activator of KCC2 activity, and small molecular 
targets WNK-SAPK kinase signaling may be a novel therapeutic 
strategy for epilepsy. 
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